High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates

References

• World Health Organization. Global tuberculosis report 2021; [cited 16 December 2021]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
   Google Scholar
• WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. [cited 28 December 2021]. Available from: https://www.who.int/publications-detail-redirect/9789240007048.
   Google Scholar
• Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis; [cited 10 February 2022]. Available from: https://www.who.int/publications-detail-redirect/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis.
   Google Scholar
• Chaiyachat P, Chaiprasert A, Nonghanphithak D, et al. Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance. Int J Antimicrob Agents. 2021;58:106385.
   PubMed Web of Science ®Google Scholar
• Meehan CJ, Moris P, Kohl TA, et al. The relationship between transmission time and clustering methods in Mycobacterium tuberculosis epidemiology. EBioMedicine. 2018;37:410–416.
   PubMed Web of Science ®Google Scholar
• Srilohasin P, Prammananan T, Faksri K, et al. Genomic evidence supporting the clonal expansion of extensively drug-resistant tuberculosis bacteria belonging to a rare proto-Beijing genotype. Emerg Microbes Infect. 2020;9:2632–2641.
   PubMed Web of Science ®Google Scholar
• Nonghanphithak D, Chaiprasert A, Smithtikarn S, et al. Clusters of drug-resistant Mycobacterium tuberculosis detected by whole-genome sequence analysis of nationwide sample, Thailand, 2014–2017. Emerg Infect Dis. 2021;27:813–822.
   PubMed Web of Science ®Google Scholar
• Chen X, He G, Wang S, et al. Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in Clinical multi-drug resistance Mycobacterium tuberculosis isolates from China. Front Microbiol. 2019;10:1–10.
   PubMed Web of Science ®Google Scholar
• Jabbar A, Phelan JE, de Sessions PF, et al. Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of north West Pakistan. Sci Rep. 2019;9:1–9.
   PubMed Web of Science ®Google Scholar
• Ali A, Hasan Z, McNerney R, et al. Whole genome sequencing based Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan. PLoS One. 2015;10:1–17.
   Web of Science ®Google Scholar
• Coll F, Phelan J, Hill-Cawthorne GA, et al. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet. 2018;50:307–316.
   PubMed Web of Science ®Google Scholar
• Farhat MR, Freschi L, Calderon R, et al. GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nat Commun. 2019;10:2128.
   PubMed Web of Science ®Google Scholar
• Santos-Lazaro D, Gavilan RG, Solari L, et al. Whole genome analysis of extensively drug resistant Mycobacterium tuberculosis strains in Peru. Sci Rep. 2021;11:9493.
   PubMed Web of Science ®Google Scholar
• Soundararajan L, Kambli P, Priyadarshini S, et al. Whole genome enrichment approach for rapid detection of Mycobacterium tuberculosis and drug resistance-associated mutations from direct sputum sequencing. Tuberculosis. 2020;121:101915.
   PubMed Web of Science ®Google Scholar
• Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15:1193–1202.
   PubMed Web of Science ®Google Scholar
• Definitions and reporting framework for tuberculosis. [cited 9 January 2022]. Available from: https://www.who.int/publications-detail-redirect/9789241505345.
   Google Scholar
• Coll F, McNerney R, Preston MD, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 2015;7:51.
   PubMed Web of Science ®Google Scholar
• Kapopoulou A, Lew JM, Cole ST. The MycoBrowser portal: a comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis (Edinb). 2011;91:8–13.
   PubMed Web of Science ®Google Scholar
• Benavente ED, Coll F, Furnham N, et al. PhyTB: phylogenetic tree visualisation and sample positioning for M. tuberculosis. BMC Bioinformatics. 2015;16:155.
   PubMed Web of Science ®Google Scholar
• Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data. [cited 9 January 2022]. Available from: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
   Google Scholar
• Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–2120.
   PubMed Web of Science ®Google Scholar
• Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997 [q-bio]. 2013.
   Google Scholar
• Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–2079.
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–1303.
   PubMed Web of Science ®Google Scholar
• Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10:giab008.
   PubMed Web of Science ®Google Scholar
• Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30:1312–1313.
   PubMed Web of Science ®Google Scholar
• Letunic I, Bork P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics. 2007;23:127–128.
   PubMed Web of Science ®Google Scholar
• Seemann T. snp-dists. 2021.
   Google Scholar
• Tiberi S, Muñoz-Torrico M, Duarte R, et al. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018;24:86–98.
   PubMed Web of Science ®Google Scholar
• Gómez-González PJ, Perdigao J, Gomes P, et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci Rep. 2021;11:19431.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang B, Hu M, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61:e00239–17.
   PubMed Web of Science ®Google Scholar
• Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. [cited 28 December 2021]. Available from: https://www.who.int/publications-detail-redirect/9789240028173.
   Google Scholar
• Zhang Z, Pang Y, Wang Y, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents. 2014;43:231–235.
   PubMed Web of Science ®Google Scholar
• Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:5316–5323.
   PubMed Web of Science ®Google Scholar
• Battaglia S, Spitaleri A, Cabibbe AM, et al. Characterization of Genomic variants associated with resistance to bedaquiline and delamanid in naive Mycobacterium tuberculosis Clinical strains. J Clin Microbiol. 2020;58:e01304–20.
   PubMed Web of Science ®Google Scholar
• Rifat D, Li S-Y, Ioerger T, et al. Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;65:e01948–20.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang S, Cui P, et al. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72:3272–3276.
   PubMed Web of Science ®Google Scholar
• Gygli SM, Borrell S, Trauner A, et al. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41:354–373.
   PubMed Web of Science ®Google Scholar
• Ioerger TR, Koo S, No E-G, et al. Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-natal, South Africa. PLOS ONE. 2009;4:e7778.
   PubMed Web of Science ®Google Scholar
• Auld SC, Shah NS, Mathema B, et al. Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. Eur Respir J. 2018;52:1800246.
   PubMed Web of Science ®Google Scholar
• Ioerger TR, Feng Y, Chen X, et al. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the western cape of South Africa. BMC Genomics. 2010;11:670.
   PubMed Web of Science ®Google Scholar
• Mlambo CK, Warren RM, Poswa X, et al. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis. 2008;12:99–104.
   PubMed Web of Science ®Google Scholar
• Knight GM, Colijn C, Shrestha S, et al. The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis. Clin Infect Dis. 2015;61:S147–S154.
   Web of Science ®Google Scholar